Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom

Epidemiology and Infection

Volumn 136, Issue 1, 2008, Pages 44-55

  Lorgelly, P K ^a   Joshi, D ^b   Gómara, M Iturriza ^c   Gray, J ^c   Mugford, M ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UK   (United Kingdom)

^c HPA Specialist/Ref Microbiol Div   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DRUG COST; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PREVENTIVE HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM; VIRAL GASTROENTERITIS; VIRUS INFECTION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GASTROENTERITIS; GREAT BRITAIN; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; PATIENT ACCEPTANCE OF HEALTH CARE; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; STATE MEDICINE; VACCINATION;

EID: 37549055421     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807008151     Document Type: Article

References (47)

1. Iturriza Gomara M, et al. Structured surveillance of infantile gastroenteritis in East Anglia, UK: Incidence of infection with common viral gastroenteric pathogens. Epidemiology and Infection 2007. doi:10.1017/S0950268807008059.
2. Lorgelly PK, et al. Infantile gastroenteritis in the community: A cost-of-illness study. Epidemiology and Infection; 2007. doi:10.1017/S0950268807008163.
3. Parashar UD, et al. Global illness and deaths caused by rotavirus disease in children. Emerging Infectious Diseases 2003; 9: 565-572.
4. Smith JC, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995; 96 609-615.
5. Tucker AW, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Journal of the American Medical Association 1998; 279: 1371-1376.
6. Vesikari T, Giaquinto C, Huppertz HI. Clinical trials of rotavirus vaccines in Europe. Pediatric Infectious Disease Journal 2006; 25: S42 S47.
7. Ruiz-Palacios GM, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine 2006; 354: 11-22.
8. Vesikari T, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine 2006; 354: 23-33.
9. Carlin JB, et al. Cost effectiveness of rotavirus vaccination in Australia. Australian and New Zealand Journal of Public Health 1999; 23: 611-616.
10. Isakbaeva ET, et al. Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine. Vaccine 2007; 25: 373-380.
11. Netten A, Curtis L. Unit Costs of Health and Social Care 2006 PSSRU, University of Kent at Canterbury, 2006.
12. HM Treasury. The Green Book. London, Stationery Office, 2003.
13. Office of Population Censuses and Surveys, Department of Health, Royal College of General Practitioners. Morbidity Statistics from General Practice: Fourth National Study 1991-1992. London: HMSO, 1995.
14. Office for National Statistics. Age Structure of England and Wales 1961-2074. ONS Population Estimates (http://www.statistics.gov.uk/ populationestimates/svg_pyramid/default.htm). Accessed 29 December 2006.
15. Isaacs D, Day D, Crook S. Childhood gastroenteritis: A population study. British Medical Journal 1986; 293: 545-546.
16. Soriano-Gabarrò, M, et al. Burden of rotavirus disease in European Union countries. Pediatric Infectious Disease Journal 2006; 25: S7-S11.
17. Office of National Statistics. Provision and use of services, in The Health of Children and Young People, 2004 (http://www.statistics.gov.uk/Children/downloads/prov_use_services.pdf). Accessed 29 December 2006.
18. Armon K, et al. The impact of presenting problem based guidelines for children with medical problems in an accident and emergency department. Archives of Disease in Childhood 2004; 89 159-164.
19. Cilla G, et al. Incidence, seasonality and serotypes of rotavirus in Gipuzkoa (Basque Country), Spain. A 14-year study. Epidemiology and Infection 2000; 125: 677-683.
20. Joensuu J, et al. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350: 1205-1209.
21. Ryan MJ, et al. Hospital admissions attributable to rotavirus infection in England and Wales. Journal of Infectious Diseases 1996; 174 (Suppl. 1): 12-18.
22. Crowley DS, Ryan MJ, Wall PG. Gastroenteritis in children under 5 years of age in England and Wales. Communicable Disease Report. CDR Review 1997; 7: R82-R86.
23. Offit PA, Coffin SE. Communicating science to the public: MMR vaccine and autism. Vaccine 2003; 22: 1-6.
24. Department of Health. NHS Immunisation Statistics, England: 2005-06 (http://www.publications.doh.gov.uk/public/sb0416.pdf). Accessed 20 November 2006.
25. Vesikari T, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatric Infectious Disease Journal 2004; 23: 937-943.
26. De Vos B, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatric Infectious Disease Journal 2004; 23: 179-182.
27. Clark HF, et al. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) - human rotavirus reassortants. Pediatric Infectious Disease Journal 2006; 25: 577-583.
28. Soares-Weiser K, et al. Rotavirus vaccine for preventing diarrhoea. Cochrane Database of Systematic Reviews 2004. Art. no.: CD002848.
29. Netten A, Curtis L. Unit Costs of Health and Social Care 2005 PSSRU, University of Kent at Canterbury, 2005.
30. Noel JS, et al. Impact of rotavirus infection on a paediatric hospital in the east end of London. Journal of Clinical Pathology 1994; 47: 67-70.
31. Gil A, et al. Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999 2000. Vaccine 2004; 22: 2221-2225.
32. The Comptroller and Auditor General. NHS Direct in England. London, 2002
33. Munro J, et al. Evaluation of NHS Direct First Wave Sites: Final Report of the Phase 1 Research. Medical Care Research Unit, University of Sheffield, 2001.
34. British Medical Association & Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ, 2002.
35. Walling A. Families and Work. Labour Market Trends; Office of National Statistics, July 2005.
36. Office of National Statistics. Living in Britain: Results From the 2002 General Household Survey. Palgrave: Macmillan, 2004.
37. Office for National Statistics. First Release 2006: Annual Survey of Hours and Earnings (http://www.statistics.gov.uk/pdfdir/ ashe1006.pdf). Accessed 15 December 2006.
38. Harding L. Children's quality of life assessments: A review of generic and health related quality of life measures completed by children and adolescents. Clinical Psychology and Psychotherapy 2001; 8: 79-96.
39. Wallander JL, Schmitt M, Koot HM. Quality of life measurement in children and adolescents: Issues, instruments, and applications. Journal of Clinical Psychology 2001; 57: 571-585.
40. Raat H, et al. Reliability and validity of comprehensive health status measures in children: The Child Health Questionnaire in relation to the Health Utilities Index. Journal of Clinical Epidemiology 2002; 55: 67-76.
41. World Health Organization. WHO-CHOICE: CHO-osing INterventions that are Cost Effective: Cost-effectiveness thresholds (http://www.who.int/choice/costs/CER_levels/en/index.html). Accessed 10 January 2007.
42. National Institute for Clinical Excellence. Guide to the methods of technology appraisal, April 2004 (http://www.nice.org.uk/pdf/ TAP_Methods.pdf). Accessed 20 November 2006.
43. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: A critical review of published cost-utility studies in child health. Pediatrics 2005; 115: 600-614.
44. Rheingans RD, Heylen J, Giaquinto C. Economics of rotavirus gastroenteritis and vaccination in Europe: What makes sense? Pediatric Infectious Disease Journal 2006; 25: S48-S55.
45. Sansom SL, et al. Rotavirus vaccine and intussusception: How much risk will parents in the United States accept to obtain vaccine benefits? American Journal of Epidemiology 2001; 154: 1077-1085.
46. Marshall J, et al. Rotavirus detection and characterisation in outbreaks of gastroenteritis in aged-care facilities. Journal of Clinical Virology 2003; 28: 331-340.
47. Anderson EJ, Weber SG. Rotavirus infection in adults. Lancet Infectious Diseases 2004; 4: 91-99.